scholarly journals Use of FDG-PET in Radiation Treatment Planning for Thoracic Cancers

2012 ◽  
Vol 2012 ◽  
pp. 1-9 ◽  
Author(s):  
Katsuyuki Shirai ◽  
Akiko Nakagawa ◽  
Takanori Abe ◽  
Masahiro Kawahara ◽  
Jun-ichi Saitoh ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Esophageal Cancer ◽  
Cancer Patients ◽  
Fdg Pet ◽  
Radiation Treatment ◽  
Biological Information ◽  
Radiotherapy Planning ◽  
Lung Cancer Patients ◽  
Tumor Delineation ◽  
Curative Radiotherapy

Radiotherapy plays an important role in the treatment for thoracic cancers. Accurate diagnosis is essential to correctly perform curative radiotherapy. Tumor delineation is also important to prevent geographic misses in radiotherapy planning. Currently, planning is based on computed tomography (CT) imaging when radiation oncologists manually contour the tumor, and this practice often induces interobserver variability. F-18 fluorodeoxyglucose positron emission tomography (FDG-PET) has been reported to enable accurate staging and detect tumor extension in several thoracic cancers, such as lung cancer and esophageal cancer. FDG-PET imaging has many potential advantages in radiotherapy planning for these cancers, because it can add biological information to conventional anatomical images and decrease the inter-observer variability. FDG-PET improves radiotherapy volume and enables dose escalation without causing severe side effects, especially in lung cancer patients. The main advantage of FDG-PET for esophageal cancer patients is the detection of unrecognized lymph node or distal metastases. However, automatic delineation by FDG-PET is still controversial in these tumors, despite the initial expectations. We will review the role of FDG-PET in radiotherapy for thoracic cancers, including lung cancer and esophageal cancer.

INTRA-ACQUISITION VARIABILITY DURING PET/CT IN LUNG CANCER PATIENTS – IMPLICATIONS FOR RADIOTHERAPY-PLANNING

2009 ◽  
Vol 92 ◽  
pp. S41
Author(s):  
N. Marmouk ◽  
E. Van Mierlo ◽  
B. Verhoeven ◽  
A. Arens ◽  
M. van de Pol
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Radiotherapy Planning ◽  
Lung Cancer Patients ◽  
Pet Ct

scholarly journals Dynamic PET/CT Imaging of 68Ga-FAPI-04 in Chinese Subjects

2021 ◽  
Vol 11 ◽  
Author(s):  
Shuailiang Wang ◽  
Xin Zhou ◽  
Xiaoxia Xu ◽  
Jin Ding ◽  
Teli Liu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Body Mass ◽  
Fdg Pet ◽  
Radiation Dosimetry ◽  
Ct Imaging ◽  
Lung Cancer Patients ◽  
Pet Ct ◽  
Fdg Pet Ct ◽  
Chinese Subjects

This study aims to further explore dynamic 68Ga-FAPI-04 PET/CT imaging of healthy Chinese subjects and lung cancer patients. Moreover, the variability of 68Ga-FAPI-04 uptake in normal organs was measured to provide a basis for analyzing its biological distribution, interpreting auxiliary images, determining the reliability of image quantification, and monitoring treatment. Six patients (3 subjects without tumors and 3 lung cancer patients) separately underwent 68Ga-FAPI-04 and 2-[18F]FDG PET/CT imaging within 1 week. The biodistribution and internal radiation dosimetry were reported and compared with data previously obtained from Caucasian patients. Moreover, the mean SUV (standardized uptake value) was normalized to body mass or to lean body mass (SUL), and the coefficients of variation (CVs) were calculated and compared for each volume of interest. The average whole-body effective dose was calculated to be 1.27E-02 mSv/MBq, which was comparable with previously reported results of 68Ga-FAPI-04 probes. Furthermore, the SUVmean was slightly higher than the SULmean in most organs; however, the CV of the SULmean for most organs was higher than that of the SUVmean at later time points. In the liver, the CV of the SUVmean was lower (12.7%) than that of the SULmean and was similar to the CV for corresponding 2-[18F]FDG PET/CT value (11.8%). In addition, 68Ga-FAPI-04 PET/CT showed good efficacy for diagnosing lung cancer patients in this study. A comparison of the radiation dosimetry obtained before from a Caucasian population demonstrated no clinically significant differences between these two populations after 68Ga-FAPI-04 injection. The variability in most organs was slightly lower for SUVmean than for SULmean, suggesting that SUVmean may be the preferable parameter for quantifying images obtained with 68Ga-FAPI-04. In addition, 68Ga-FAPI-04 PET/CT imaging is expected to be a promising tool for diagnosing lung cancer.

Systematic intrafraction shifts of mediastinal lymph node targets between setup imaging and radiation treatment delivery in lung cancer patients

2018 ◽  
Vol 126 (2) ◽  
pp. 318-324 ◽  
Author(s):  
Mai Lykkegaard Schmidt ◽  
Lone Hoffmann ◽  
Ditte S. Møller ◽  
Marianne Marquard Knap ◽  
Torben Riis Rasmussen ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Lymph Node ◽  
Cancer Patients ◽  
Radiation Treatment ◽  
Mediastinal Lymph Node ◽  
Treatment Delivery ◽  
Lung Cancer Patients

scholarly journals PET/CT and the Response to Immunotherapy in Lung Cancer

2020 ◽  
Vol 13 (3) ◽  
pp. 177-184 ◽  
Author(s):  
Laura Evangelista ◽  
Matteo Sepulcri ◽  
Giulia Pasello
Keyword(s):  
Lung Cancer ◽  
Clinical Trials ◽  
Cancer Patients ◽  
Fdg Pet ◽  
Response To Therapy ◽  
Prediction Of Response ◽  
Lung Cancer Patients ◽  
Pet Ct ◽  
Fdg Pet Ct

Objective: In recent years, the introduction of immune checkpoint inhibitors has significantly changed the outcome of patients affected by lung cancer and cutaneous melanoma. Although the clinical advantages, the selection of patients and the evaluation of response to immunotherapy remain unclear, the immune-related Response Evaluation Criteria in Solid Tumor (irRECIST) was proposed as an update of the RECIST criteria for the assessment of response to immunotherapy. However, morphological images cannot predict early response to therapy that represents a challenge in clinical practice. 18F-FDG PET/CT before and after immunotherapy has an indeterminate role, demonstrating ambiguous results due to inflammatory effects secondary to activation of the immune system. The aim of the present review was to analyze the role of PET/CT as a guide for immunotherapy, by analyzing the current status and future perspectives. Methods: A literature search was conducted in order to select all papers that discussed the role of PET/CT with FDG or other tracers in the evaluation or prediction of response to immunotherapy in lung cancer patients. Results: Many papers are now available. Many clinical trials have demonstrated the efficacy of immunotherapy in lung cancer patients. FDG PET/CT can be used for the prediction of response to immunotherapy, while its utility for the evaluation of response is not still clearly reported. Moreover, the standardization of FDG PET/CT interpretation is missing and different criteria, such as information, have been investigated until now. Conclusions: The utility of FDG PET/CT for patients with lung cancer undergoing immunotherapies is still preliminary and not well addressed. New agents for PET are promising, but large clinical trials are mandatory.

Value of Dual-Time-Point FDG PET/CT for Mediastinal Nodal Staging in Non-Small-Cell Lung Cancer Patients With Lung Comorbidity

2011 ◽  
Vol 36 (6) ◽  
pp. 429-433 ◽  
Author(s):  
Man Hu ◽  
Anqin Han ◽  
Ligang Xing ◽  
Wenfeng Yang ◽  
Zheng Fu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Fdg Pet ◽  
Small Cell ◽  
Nodal Staging ◽  
Small Cell Lung ◽  
Lung Cancer Patients ◽  
Pet Ct ◽  
Fdg Pet Ct ◽  
Time Point
Sign in / Sign up

Export Citation Format

Share Document